These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33855021)

  • 21. PGM3 inhibition shows cooperative effects with erastin inducing pancreatic cancer cell death
    Zerbato B; Gobbi M; Ludwig T; Brancato V; Pessina A; Brambilla L; Wegner A; Chiaradonna F
    Front Oncol; 2023; 13():1125855. PubMed ID: 37260977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
    Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
    Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-200a Suppresses the Proliferation and Metastasis in Pancreatic Ductal Adenocarcinoma through Downregulation of DEK Gene.
    Wu X; Wu G; Wu Z; Yao X; Li G
    Transl Oncol; 2016 Feb; 9(1):25-31. PubMed ID: 26947878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
    Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
    Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.
    Yao M; Hong Y; Liu Y; Chen W; Wang W
    Exp Ther Med; 2017 Sep; 14(3):2101-2107. PubMed ID: 28962130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma.
    Wan C; Gong C; Ji L; Liu X; Wang Y; Wang L; Shao M; Yang L; Fan S; Xiao Y; Wang X; Li M; Zhou G; Zhang Y
    Mol Cell Biochem; 2015 Dec; 410(1-2):25-35. PubMed ID: 26276310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extracellular Matrix Composition Modulates the Responsiveness of Differentiated and Stem Pancreatic Cancer Cells to Lipophilic Derivate of Gemcitabine.
    Forciniti S; Dalla Pozza E; Greco MR; Amaral Carvalho TM; Rolando B; Ambrosini G; Carmona-Carmona CA; Pacchiana R; Di Molfetta D; Donadelli M; Arpicco S; Palmieri M; Reshkin SJ; Dando I; Cardone RA
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells.
    Gao Y; Chen MK; Chu YY; Yang L; Yu D; Liu Y; Hung MC
    Am J Cancer Res; 2021; 11(1):236-250. PubMed ID: 33520371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanoparticle-Mediated Therapy with miR-198 Sensitizes Pancreatic Cancer to Gemcitabine Treatment through Downregulation of VCP-Mediated Autophagy.
    Marin-Muller C; Li D; Lü JM; Liang Z; Vega-Martínez O; Crawford SE; Estes MK; Fisher WE; Chen C; Yao Q
    Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines.
    Ragone A; Salzillo A; Spina A; Naviglio S; Sapio L
    Front Pharmacol; 2022; 13():837503. PubMed ID: 35273510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KIF18B promotes the proliferation of pancreatic ductal adenocarcinoma via activating the expression of CDCA8.
    Li B; Liu B; Zhang X; Liu H; He L
    J Cell Physiol; 2020 May; 235(5):4227-4238. PubMed ID: 31875977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GATA1 Promotes Gemcitabine Resistance in Pancreatic Cancer through Antiapoptotic Pathway.
    Chang Z; Zhang Y; Liu J; Guan C; Gu X; Yang Z; Ye Q; Ding L; Liu R
    J Oncol; 2019; 2019():9474273. PubMed ID: 31093285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TMPRSS4 Promotes Cell Proliferation and Inhibits Apoptosis in Pancreatic Ductal Adenocarcinoma by Activating ERK1/2 Signaling Pathway.
    Gu J; Huang W; Zhang J; Wang X; Tao T; Yang L; Zheng Y; Liu S; Yang J; Zhu L; Wang H; Fan Y
    Front Oncol; 2021; 11():628353. PubMed ID: 33816264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis.
    Hung WC; Lee DY; Chiang EI; Syu JN; Chao CY; Yang MD; Tsai SY; Tang FY
    PLoS One; 2020; 15(11):e0241186. PubMed ID: 33137095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma.
    Wang C; Sun Y; Wu H; Yu S; Zhang L; Meng Y; Liu M; Yang H; Liu P; Mao X; Lu Z; Chen J
    Tumour Biol; 2015 Dec; 36(12):9447-56. PubMed ID: 26124009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
    Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
    Front Oncol; 2020; 10():1112. PubMed ID: 32850319
    [No Abstract]   [Full Text] [Related]  

  • 38. Adjuvant nab-paclitaxel plus gemcitabine
    Yin ZZ; Zhao ZM; Tang WB; Jiang N; Zhang KD; Song YY; Wang Y; Li CG; Gao YX; Liu R
    World J Clin Cases; 2020 Jul; 8(13):2778-2786. PubMed ID: 32742988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice.
    Kwegyir-Afful AK; Murigi FN; Purushottamachar P; Ramamurthy VP; Martin MS; Njar VCO
    Oncotarget; 2017 Aug; 8(32):52381-52402. PubMed ID: 28881737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.
    Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M
    Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.